Glioblastoma (GBM) is one of the most aggressive cancers, characterized by a decrease in antioxidant levels. Evidence has demonstrated that ferulic acid (FA), a natural antioxidant particularly abundant in vegetables and fruits, could be a promising candidate for GBM treatment. Since FA shows a high instability that compromises its therapeutic application, it has been encapsulated into Nanostructured Lipid Carriers (NLCs) to improve its bioavailability in the brain. It has been demonstrated that tissue transglutaminase (TG2) is a multi-functional protein implicated in many physiological and pathological processes, including cancer. TG2 is also involved in GBM correlated with metastasis formation and drug resistance. Therefore, the evaluation of TG2 expression levels and its cellular localization are important to assess the anti-cancer effect of FA against GBM cancer. Our results have demonstrated that treatment with free FA and FA-NLCs in the U87-MG cancer cell line differently modified TG2 localization and expression levels. In the cells treated with free FA, TG2 appeared expressed both in the cytosol and in the nucleus, while the treatment with FA-NLCs showed that the protein is exclusively localized in the cytosol, exerting its pro-apoptotic effect. Therefore, our data suggest that FA loaded in NLCs could represent a promising natural agent for supplementing the current anti-cancer drugs used for the treatment of GBM.

Dell’Albani, P., Carbone, C., Sposito, G., Spatuzza, M., Chiacchio, M., Grasso, R., et al. (2024). Effect of Ferulic Acid loaded in Nanoparticle on tissue transglutaminase expression levels in human glioblastoma cell line. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25(15) [10.3390/ijms25158397].

Effect of Ferulic Acid loaded in Nanoparticle on tissue transglutaminase expression levels in human glioblastoma cell line

Legnani L;
2024

Abstract

Glioblastoma (GBM) is one of the most aggressive cancers, characterized by a decrease in antioxidant levels. Evidence has demonstrated that ferulic acid (FA), a natural antioxidant particularly abundant in vegetables and fruits, could be a promising candidate for GBM treatment. Since FA shows a high instability that compromises its therapeutic application, it has been encapsulated into Nanostructured Lipid Carriers (NLCs) to improve its bioavailability in the brain. It has been demonstrated that tissue transglutaminase (TG2) is a multi-functional protein implicated in many physiological and pathological processes, including cancer. TG2 is also involved in GBM correlated with metastasis formation and drug resistance. Therefore, the evaluation of TG2 expression levels and its cellular localization are important to assess the anti-cancer effect of FA against GBM cancer. Our results have demonstrated that treatment with free FA and FA-NLCs in the U87-MG cancer cell line differently modified TG2 localization and expression levels. In the cells treated with free FA, TG2 appeared expressed both in the cytosol and in the nucleus, while the treatment with FA-NLCs showed that the protein is exclusively localized in the cytosol, exerting its pro-apoptotic effect. Therefore, our data suggest that FA loaded in NLCs could represent a promising natural agent for supplementing the current anti-cancer drugs used for the treatment of GBM.
Articolo in rivista - Articolo scientifico
cell cycle progression; ferulic acid; glioblastoma; human glioma cell line; nanostructured lipid carrier (NLC); tissue transglutaminase (TG2);
English
1-ago-2024
2024
25
15
8397
open
Dell’Albani, P., Carbone, C., Sposito, G., Spatuzza, M., Chiacchio, M., Grasso, R., et al. (2024). Effect of Ferulic Acid loaded in Nanoparticle on tissue transglutaminase expression levels in human glioblastoma cell line. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25(15) [10.3390/ijms25158397].
File in questo prodotto:
File Dimensione Formato  
Dell’Albani-2024-International Journal of Molecular Sciences-VoR.pdf

accesso aperto

Descrizione: Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 4.81 MB
Formato Adobe PDF
4.81 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/509739
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact